277 related articles for article (PubMed ID: 28389693)
1. The Advantages and Challenges of Using FDG PET/CT for Response Assessment in Melanoma in the Era of Targeted Agents and Immunotherapy.
Wong ANM; McArthur GA; Hofman MS; Hicks RJ
Eur J Nucl Med Mol Imaging; 2017 Aug; 44(Suppl 1):67-77. PubMed ID: 28389693
[TBL] [Abstract][Full Text] [Related]
2.
Hicks RJ; Iravani A; Sandhu S
PET Clin; 2020 Jan; 15(1):11-22. PubMed ID: 31735298
[TBL] [Abstract][Full Text] [Related]
3. 18F-FDG PET/CT longitudinal studies in patients with advanced metastatic melanoma for response evaluation of combination treatment with vemurafenib and ipilimumab.
Sachpekidis C; Kopp-Schneider A; Hakim-Meibodi L; Dimitrakopoulou-Strauss A; Hassel JC
Melanoma Res; 2019 Apr; 29(2):178-186. PubMed ID: 30653029
[TBL] [Abstract][Full Text] [Related]
4. (18)F-FDG PET/CT and Melanoma: Staging, Immune Modulation and Mutation-Targeted Therapy Assessment, and Prognosis.
Perng P; Marcus C; Subramaniam RM
AJR Am J Roentgenol; 2015 Aug; 205(2):259-70. PubMed ID: 26204273
[TBL] [Abstract][Full Text] [Related]
5. The Role of PET/CT in the Era of Immune Checkpoint Inhibitors: State of Art.
Castello A; Lopci E
Curr Radiopharm; 2020; 13(1):24-31. PubMed ID: 31749440
[TBL] [Abstract][Full Text] [Related]
6. PET/CT and the Response to Immunotherapy in Lung Cancer.
Evangelista L; Sepulcri M; Pasello G
Curr Radiopharm; 2020; 13(3):177-184. PubMed ID: 31858908
[TBL] [Abstract][Full Text] [Related]
7. (18)F-labelled fluorodeoxyglucose-positron emission tomography (FDG-PET) heterogeneity of response is prognostic in dabrafenib treated BRAF mutant metastatic melanoma.
Carlino MS; Saunders CA; Haydu LE; Menzies AM; Martin Curtis C; Lebowitz PF; Kefford RF; Long GV
Eur J Cancer; 2013 Jan; 49(2):395-402. PubMed ID: 22981500
[TBL] [Abstract][Full Text] [Related]
8. Diffuse Large B-Cell Lymphoma: Prospective Multicenter Comparison of Early Interim FLT PET/CT versus FDG PET/CT with IHP, EORTC, Deauville, and PERCIST Criteria for Early Therapeutic Monitoring.
Minamimoto R; Fayad L; Advani R; Vose J; Macapinlac H; Meza J; Hankins J; Mottaghy F; Juweid M; Quon A
Radiology; 2016 Jul; 280(1):220-9. PubMed ID: 26854705
[TBL] [Abstract][Full Text] [Related]
9. Correlation between early 18F-FDG PET/CT response to BRAF and MEK inhibition and survival in patients with BRAF-mutant metastatic melanoma.
Schmitt RJ; Kreidler SM; Glueck DH; Amaria RN; Gonzalez R; Lewis K; Bagrosky BM; Kwak JJ; Koo PJ
Nucl Med Commun; 2016 Feb; 37(2):122-8. PubMed ID: 26440571
[TBL] [Abstract][Full Text] [Related]
10. Predictive value of early 18F-FDG PET/CT studies for treatment response evaluation to ipilimumab in metastatic melanoma: preliminary results of an ongoing study.
Sachpekidis C; Larribere L; Pan L; Haberkorn U; Dimitrakopoulou-Strauss A; Hassel JC
Eur J Nucl Med Mol Imaging; 2015 Mar; 42(3):386-96. PubMed ID: 25359635
[TBL] [Abstract][Full Text] [Related]
11. Therapy response monitoring of the early effects of a new BRAF inhibitor on melanoma xenograft in mice: evaluation of (18) F-FDG-PET and (18) F-FLT-PET.
Geven EJ; Evers S; Nayak TK; Bergström M; Su F; Gerrits D; Franssen GM; Boerman OC
Contrast Media Mol Imaging; 2015; 10(3):203-10. PubMed ID: 25204436
[TBL] [Abstract][Full Text] [Related]
12. Monitoring metabolic response using FDG PET-CT during targeted therapy for metastatic colorectal cancer.
Woff E; Hendlisz A; Garcia C; Deleporte A; Delaunoit T; Maréchal R; Holbrechts S; Van den Eynde M; Demolin G; Vierasu I; Lhommel R; Gauthier N; Guiot T; Ameye L; Flamen P
Eur J Nucl Med Mol Imaging; 2016 Sep; 43(10):1792-801. PubMed ID: 27072811
[TBL] [Abstract][Full Text] [Related]
13. Metastatic melanoma response to combination therapy with ipilimumab and vemurafenib.
Sachpekidis C; Hassel JC; Dimitrakopoulou-Strauss A
Hell J Nucl Med; 2017; 20(3):251-253. PubMed ID: 29177265
[TBL] [Abstract][Full Text] [Related]
14. FDG PET/CT for Assessment of Immune Therapy: Opportunities and Understanding Pitfalls.
Cho SY; Huff DT; Jeraj R; Albertini MR
Semin Nucl Med; 2020 Nov; 50(6):518-531. PubMed ID: 33059821
[TBL] [Abstract][Full Text] [Related]
15. Current Evidence on PET Response Assessment to Immunotherapy in Lymphomas.
Lopci E; Meignan M
PET Clin; 2020 Jan; 15(1):23-34. PubMed ID: 31735299
[TBL] [Abstract][Full Text] [Related]
16. The predictive power of FDG-PET imaging with regard to immunotherapy in real-life conditions in advanced melanoma: An exploratory study.
Blanchet K; Sebille JC; Frenard C; Lecerf P; Khammari A; Carlier T; Bodet-Milin C; Dréno B
J Eur Acad Dermatol Venereol; 2023 Jan; 37(1):e61-e62. PubMed ID: 35974443
[No Abstract] [Full Text] [Related]
17. [Melanoma: introduction and special demands on radiology].
Schiller M; Hassel JC
Radiologe; 2015 Feb; 55(2):93-8. PubMed ID: 25609505
[TBL] [Abstract][Full Text] [Related]
18. Nivolumab-Induced Pneumonitis in Patient With Metastatic Melanoma Showing Complete Remission on 18F-FDG PET/CT.
Razzouk-Cadet M; Picard A; Grangeon-Chapon C; Lacour JP; Montaudié H
Clin Nucl Med; 2019 Oct; 44(10):806-807. PubMed ID: 31306191
[TBL] [Abstract][Full Text] [Related]
19. MAPK pathway in melanoma part II-secondary and adaptive resistance mechanisms to BRAF inhibition.
Amaral T; Sinnberg T; Meier F; Krepler C; Levesque M; Niessner H; Garbe C
Eur J Cancer; 2017 Mar; 73():93-101. PubMed ID: 28162869
[TBL] [Abstract][Full Text] [Related]
20. Positron emission tomography/computed tomography evaluation of oncolytic virus therapy efficacy in melanoma.
Franke V; van der Hiel B; van de Wiel BA; Klop WMC; Ter Meulen S; van Akkooi ACJ
Eur J Cancer; 2018 Feb; 90():149-152. PubMed ID: 29224902
[No Abstract] [Full Text] [Related]
[Next] [New Search]
